2-(4-Methyl-trans-styryl)thiophene-3-sulfonyl chloride | 187164-84-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-Methyl-trans-styryl)thiophene-3-sulfonyl chloride
• 英文别名: 2-[(E)-2-(4-methylphenyl)ethenyl]thiophene-3-sulfonyl chloride
• CAS: 187164-84-7
• 化学式: C₁₃H₁₁ClO₂S₂
• 分子量: 298.814
• InChiKey: FZNKSHKBBMGLOZ-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  70.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-Methyl-trans-styryl)thiophene-3-sulfonyl chloride 、 4-溴-3-甲基异噁唑-5-胺 在 crude product 作用下， 以resulting in a 34% yield, m.p. 101-105° C.的产率得到N-(4-Bromo-3-methyl-5-isoxazolyl)-2-(4-methyl-trans-styryl)thiophene-3-sulfonamide
  参考文献：
  名称：

  THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN

  摘要：

  本文提供了噻吩基、呋喃基和吡咯基磺酰胺及其调节或改变内皮素家族肽活性的方法。特别地，提供了N-(异恶唑基)噻吩磺酰胺、N-(异恶唑基)呋喃磺酰胺和N-(异恶唑基)吡咯磺酰胺，以及使用这些磺酰胺通过与受体接触来抑制内皮素肽与内皮素受体结合的方法。还提供了通过给予这些磺酰胺或其制剂的有效剂量来治疗内皮素介导的疾病的方法，这些制剂可以抑制或增加内皮素的活性。

  公开号：

  US20010021714A1
• 作为产物：
  描述：

  [3-(Pyrrole-1-sulfonyl)-thiophen-2-ylmethyl]-phosphonic acid diethyl ester 在 氢氧化钾 、 五氯化磷 、 水 、 sodium hydride 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 生成 2-(4-Methyl-trans-styryl)thiophene-3-sulfonyl chloride
  参考文献：
  名称：

  Amide bond surrogates: A study in thiophenesulfonamide based endothelin receptor antagonists

  摘要：

  The potential proteolytic instability of the amide bond present in some ETA selective thiophenesulfonamide endothelin antagonists exemplified by TBC-10708 led us to investigate the replacement of this moiety with stable amide bond surrogates such as a trans double bond and an ethylene spacer. The effect of these replacements on the binding affinity is described. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00133-9

文献信息

• Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
  申请人：——

  公开号：US20020095041A1

  公开（公告）日：2002-07-18

  Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

  提供了二苯基磺胺类化合物和调节或改变内皮素家族肽活性的方法。具体包括使用双环或三环碳或杂环环二苯基磺胺类化合物的方法，通过将该磺胺类化合物与内皮素受体接触来抑制内皮素肽与内皮素受体的结合。还提供了通过给予有效剂量的这些磺胺类化合物或其前药来治疗内皮素介导的疾病的方法，这些化合物能够抑制或增加内皮素的活性。
• Sulfonamides for treatment of endothelin-mediated disorders
  申请人：——

  公开号：US20020091270A1

  公开（公告）日：2002-07-11

  Thienylsulfonamides and their pharmaceutically acceptable derivatives, pharmaceutical compositions, articles of manufacture, combinations, lyophilized powders and methods for the treatment of endothelin diseases using these formulations and sulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.

  提供了噻唑磺胺及其药用可接受衍生物、药物组合物、制造物品、组合物、冻干粉剂以及使用这些配方和磺胺类药物治疗内皮素疾病的方法。提供了一种制备疏水性磺胺类化合物的碱金属盐的过程。该过程包括将游离磺胺类化合物溶解在有机溶剂中，在饱和的碱金属盐溶液存在下，并从有机相中回收形成的磺胺类盐的步骤。
• Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
  申请人：TEXAS BIOTECHNOLOGY CORPORATION

  公开号：EP1048657A1

  公开（公告）日：2000-11-02

  Biphenylsufonamides of the following formula and methods for modulating or altering the activity of the endothelin family of peptides are provided. The sulfonamides may be used for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide or a pharmaceutically acceptable salt, acid or ester thereof, wherein Ar2 is and wherein Ar1, R13 and R26 are as defined herein.

  提供以下式子的二苯基磺酰胺和调节或改变内皮素家族肽活性的方法。这些磺酰胺可用于通过将受体与磺酰胺或其药学上可接受的盐、酸或酯接触来抑制内皮素肽与内皮素受体的结合，其中Ar2为，Ar1，R13和R26的定义如本文所述。
• Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that
  申请人：Texas Biotechnology Corporation

  公开号：US05594021A1

  公开（公告）日：1997-01-14

  Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

  本文提供了硫酰胺类化合物和方法，用于调节或改变内皮素家族肽的活性。特别地，提供了N-(异噁唑基)噻吩基硫酰胺、N-(异噁唑基)呋喃基硫酰胺和N-(异噁唑基)吡咯基硫酰胺，以及使用这些硫酰胺抑制内皮素肽与内皮素受体的结合的方法。还提供了通过给予这些硫酰胺或其前药有效量来治疗内皮素介导的疾病的方法，该硫酰胺或前药抑制或增加内皮素的活性。
• Formulation of sulfonamides for treatment of endothelin-mediated disorders
  申请人：——

  公开号：US20010039289A1

  公开（公告）日：2001-11-08

  Formulations of pharmaceutically-acceptable salts of thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides using the formulations are provided. In particular, formulations of sodium salts of N-(isoxazolyl)-thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)-pyrrolylsulfonamides and methods using these sulfonamide salts for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide salt are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamide salts or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

  本发明提供了苯并噻唑基、呋喃基和吡咯基磺酰胺的药用可接受盐的配方以及使用这些配方调节或改变内皮素家族肽的活性的方法。具体而言，本发明提供了N-(异噁唑基)-苯并噻唑磺酰胺、N-(异噁唑基)-呋喃磺酰胺和N-(异噁唑基)-吡咯磺酰胺的钠盐配方，以及使用这些磺酰胺盐通过与受体接触来抑制内皮素肽与内皮素受体的结合的方法。本发明还提供了通过给予这些磺酰胺盐或其前药的有效量来治疗内皮素介导的疾病的方法，这些疾病可以抑制或增加内皮素的活性。